

Table 1. Parameters before and 48 weeks after treatment with L-T4 or placebo (mean±SD)

Variable	Treatment with L-thyroxine (n=31)			Treatment with placebo (n=32)		
	Before treatment	After 48 weeks	p	Before treatment	After 48 weeks	p
Thyrotropin (mU/L)	14.1 ± 9.8	1.1 ± 1.6	0.001	11.4 ± 5.8	9.9 ± 3.3	ns
Free thyroxine (pmol/L)	11.8 ± 1.6	18.2 ± 3.4	0.001	12.2 ± 1.4	12.5 ± 2.5	ns
Triiodothyronine (nmol/L)	2.0 ± 0.5	1.7 ± 0.1	0.001	1.9 ± 0.3	1.9 ± 0.1	ns
Blood elements						
Hemoglobin (g%)	13.3 ± 0.9	13.3 ± 0.8	ns	13.5 ± 1.1	13.3 ± 1.1	ns
Hematocrit (%)	40.4 ± 2.5	40.9 ± 2.6	ns	40.0 ± 3.2	40.4 ± 2.8	ns
MCV (fl)	88.2 ± 4.7	89.7 ± 4.8	ns	88.6 ± 5.0	89.8 ± 5.8	ns
MCH (pg)	29.1 ± 2.1	29.2 ± 1.4	ns	29.8 ± 1.7	29.4 ± 2.1	ns
MCHC (%)	33.0 ± 1.3	32.6 ± 1.0	ns	33.7 ± 1.2	32.8 ± 1.0	ns
Erythropoietin (IU/L)	9.8 ± 4.5	12.2 ± 7.3	0.006	12.6 ± 11.8	12.4 ± 7.1	ns
LDH (IU/L)	149.5 ± 34.8	158.2 ± 42.0	ns	152.3 ± 38.0	153.0 ± 43.4	ns
Potassium (mmol/L)	3.7 ± 0.3	3.9 ± 0.3	0.01	3.8 ± 0.3	3.8 ± 0.3	ns
Vitamin B12 (pmol/L)	357.4 ± 225.4	337.8 ± 232.2	ns	377.7 ± 112.6	371.2 ± 151.1	ns
Folic acid (nmol/L)	4.8 ± 2.4	4.3 ± 2.2	ns	4.5 ± 1.6	4.3 ± 2.5	ns
Leukocytes (x10 ⁹ /L)	5.2 ± 1.5	5.3 ± 1.4	ns	6.2 ± 2.0	6.2 ± 1.6	ns
Eosinophils (%)	2.4 ± 1.9	3.0 ± 2.4	0.01	2.8 ± 1.3	2.8 ± 1.3	ns
Basophils (%)	0.8 ± 0.4	0.7 ± 0.3	ns	0.7 ± 0.2	0.7 ± 0.3	ns
Neutrophils (%)	57.8 ± 7.0	59.3 ± 7.0	ns	58.7 ± 10.0	57.1 ± 8.0	ns
Lymphocytes (%)	30.5 ± 6.4	27.8 ± 5.9	0.01	29.8 ± 9.2	30.6 ± 7.4	ns
Monocytes (%)	6.0 ± 1.6	6.6 ± 1.9	0.04	6.0 ± 1.2	6.4 ± 1.5	ns

Significance was determined by Wilcoxon matched pair test.